Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kyle Eskridge

Rheumatology Wading River, NY Physician Assistant

NPI 1649740374 CMS profile 5690717

6144 Route 25A Ste 13, Wading River, NY 11792

Open in the dashboard

General payments

$21,085

819 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kyle Eskridge of Wading River, NY is reported in the CMS Open Payments database as having received $21,085 across 819 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,839 232
2024 General $4,546 181
2023 General $3,399 136
2022 General $4,083 171
2021 General $3,218 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyle Eskridge
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Kyle Eskridge were reported at $5,839. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Kyle Eskridge Rheumatology median Middle half National median
2019 $0 $744 $153–$2,687 $163
2020 $0 $462 $98–$2,027 $114
2021 $3,218 $531 $101–$2,153 $132
2022 $4,083 $627 $125–$2,303 $149
2023 $3,399 $741 $145–$2,524 $160
2024 $4,546 $830 $166–$2,660 $164
2025 $5,839 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $3,499 133 payments
  2. Janssen Biotech, Inc. $3,223 120 payments
  3. AbbVie, Inc. $2,890 100 payments
  4. Mallinckrodt Hospital Products Inc. $2,423 65 payments
  5. Horizon Therapeutics plc $1,758 45 payments
  6. Pfizer Inc. $1,041 88 payments
  7. UCB, Inc. $875 43 payments
  8. Novartis Pharmaceuticals Corporation $802 43 payments
  9. ANI Pharmaceuticals, Inc. $668 31 payments
  10. AstraZeneca Pharmaceuticals LP $576 22 payments
  11. Other $3,330 129 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $19,974 797 payments
  2. Honoraria $633 1 payment
  3. Education $478 21 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $3,187 117 payments
  2. RINVOQ $2,588 86 payments
  3. ACTHAR $2,423 65 payments
  4. KRYSTEXXA Krystexxa $1,534 34 payments
  5. SIMPONI ARIA $1,247 35 payments
  6. EVENITY $1,024 35 payments
  7. XELJANZ $1,002 86 payments
  8. Otezla $889 32 payments
  9. KRYSTEXXA Inflammation/Rare Disease $642 23 payments
  10. Prolia $566 27 payments
  11. Other $9,453 448 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

3,086

Median for Internal Medicine: 777

Drug cost

$1,841,622

Median for Internal Medicine: $73,373

Branded share of claims

16.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 54 $452,022
Enbrel Sureclick Etanercept Brand 31 $299,018
Tremfya Guselkumab Brand 13 $175,896
Xeljanz Xr Tofacitinib Citrate Brand 32 $172,972
Diclofenac Sodium Generic 120 $138,957
Humira(Cf) Pen Adalimumab Brand 21 $137,423
Otezla Apremilast Brand 27 $119,537
Cosentyx Sensoready (2 Pens) Secukinumab Brand 13 $98,040
Orencia Clickject Abatacept Brand 16 $89,021
Benlysta Belimumab Brand 14 $66,046

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $637
$637 13 —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $634
$634 — —
RINVOQ
  • AbbVie, Inc. $569
$569 54 —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $282
$282 — —
XELJANZ
  • PFIZER INC. $274
$274 32 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

819 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record